Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT005 gene therapy in geographic atrophy due to AMD
NCT03846193Phase 2Terminated
- Sponsor
- Gyroscope Therapeutics
- Start
- Dec 2018
- Primary completion
- Jun 2024
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 2
01
Overview
Phase 2, open-label trial of GT005 in geographic atrophy (GA) (5 arms), sponsored by Gyroscope Therapeutics. Primary endpoints: Ocular Treatment Emergent Adverse Events by Primary System Organ Class and Preferred Term for the Study Eye at 240 weeks, Summary of Non-Ocular Treatment Emergent Adverse Events at 240 weeks and 1 more. Started Dec 2018; status: terminated.
02
Drugs
GT005
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT03846193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03846193.